Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.
Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Danese S, et al. Among authors: rath n. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2324-2332.e6. doi: 10.1016/j.cgh.2021.06.011. Epub 2021 Jun 12. Clin Gastroenterol Hepatol. 2021. PMID: 34126262 Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S, Oemar B, Johnson K, Rath N, Salganik M, Berman G, Pelletier K, Cox L, Page K, Messing D, Tarabar S. Neelakantan S, et al. Among authors: rath n. Clin Pharmacol Drug Dev. 2021 Mar;10(3):307-316. doi: 10.1002/cpdd.887. Epub 2020 Dec 22. Clin Pharmacol Drug Dev. 2021. PMID: 33352008 Clinical Trial.
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S. Danese S, et al. Among authors: rath n. Gut. 2019 Jan;68(1):40-48. doi: 10.1136/gutjnl-2017-314562. Epub 2017 Dec 15. Gut. 2019. PMID: 29247068 Free PMC article. Clinical Trial.
Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.
Tammara BK, Sullivan JE, Adcock KG, Kierkus J, Giblin J, Rath N, Meng X, Maguire MK, Comer GM, Ward RM. Tammara BK, et al. Among authors: rath n. Clin Pharmacokinet. 2011 Aug;50(8):541-50. doi: 10.2165/11591900-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21740077 Clinical Trial.
Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease.
Kierkus J, Furmaga-Jablonska W, Sullivan JE, David ES, Stewart DL, Rath N, Fu C, Wang W, Maguire MK, Comer GM. Kierkus J, et al. Among authors: rath n. Dig Dis Sci. 2011 Feb;56(2):425-34. doi: 10.1007/s10620-010-1321-3. Epub 2010 Jul 7. Dig Dis Sci. 2011. PMID: 20607405 Clinical Trial.
A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.
Ward RM, Kearns GL, Tammara B, Bishop P, O'Gorman MA, James LP, Katz MH, Maguire MK, Rath N, Meng X, Comer GM. Ward RM, et al. Among authors: rath n. J Clin Pharmacol. 2011 Jun;51(6):876-87. doi: 10.1177/0091270010377501. Epub 2010 Sep 17. J Clin Pharmacol. 2011. PMID: 20852004 Free PMC article. Clinical Trial.
Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis.
Hogan D, Pratha V, Riff D, Ducker S, Schwartz H, Soffer E, Wang W, Rath N, Comer GM. Hogan D, et al. Among authors: rath n. Aliment Pharmacol Ther. 2007 Jul 15;26(2):249-56. doi: 10.1111/j.1365-2036.2007.03375.x. Aliment Pharmacol Ther. 2007. PMID: 17593070 Free article. Clinical Trial.
Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis.
Kumar AKH, Kadam A, Karunaianantham R, Tamizhselvan M, Padmapriyadarsini C, Mohan A, Jeyadeepa B, Radhakrishnan A, Singh UB, Bapat S, Mane A, Kumar P, Mamulwar M, Bhavani PK, Haribabu H, Rath N, Guleria R, Khan AM, Menon J; METRIF Team. Kumar AKH, et al. Among authors: rath n. Ther Drug Monit. 2024 Jun 1;46(3):370-375. doi: 10.1097/FTD.0000000000001149. Epub 2023 Nov 28. Ther Drug Monit. 2024. PMID: 38019456 Free PMC article. Clinical Trial.
373 results